{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:35:36Z","timestamp":1791599736460,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T00:00:00Z","timestamp":1699920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Health\/National Cancer Institute","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Neoadjuvant chemotherapy (NAC) before radical cystectomy is standard of care in patients with muscle-invasive bladder cancer (MIBC). Response assessment after NAC is important but suboptimal using CT. We assessed MRI without vs. with intravenous contrast (biparametric [BP] vs. multiparametric [MP]) for identifying residual disease on cystectomy and explored its prognostic role.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Consecutive MIBC patients that underwent NAC, MRI, and cystectomy between January 2000\u2013November 2022 were identified. Two radiologists reviewed BP-MRI (T2\u2009+\u2009DWI) and MP-MRI (T2\u2009+\u2009DWI\u2009+\u2009DCE) for residual tumor. Diagnostic performances were compared using receiver operating characteristic curve analysis. Kaplan-Meier curves and Cox proportional-hazards models were used to evaluate association with disease-free survival (DFS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>61 patients (36 men and 25 women; median age 65 years, interquartile range 59\u201372) were included. After NAC, no residual disease was detected on pathology in 19 (31.1%) patients. BP-MRI was more accurate than MP-MRI for detecting residual disease after NAC: area under the curve\u2009=\u20090.75 (95% confidence interval (CI), 0.62\u20130.85) vs. 0.58 (95% CI, 0.45\u20130.70; p\u2009=\u20090.043). Sensitivity were identical (65.1%; 95% CI, 49.1\u201379.0) but specificity was higher in BP-MRI compared with MP-MRI for determining residual disease: 77.8% (95% CI, 52.4\u201393.6) vs. 38.9% (95% CI, 17.3\u201364.3), respectively. Positive BP-MRI and residual disease on pathology were both associated with worse DFS: hazard ratio (HR)\u2009=\u20094.01 (95% CI, 1.70\u20139.46; p\u2009=\u20090.002) and HR\u2009=\u20095.13 (95% CI, 2.66\u201317.13; p\u2009=\u20090.008), respectively. Concordance between MRI and pathology results was significantly associated with DFS. Concordant positive (MRI+\/pathology+) patients showed worse DFS than concordant negative (MRI-\/pathology-) patients (HR\u2009=\u20098.75, 95% CI, 2.02\u201337.82; p\u2009=\u20090.004) and compared to the discordant group (MRI+\/pathology- or MRI-\/pathology+) with HR\u2009=\u20093.48 (95% CI, 1.39\u20138.71; p\u2009=\u20090.014).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>BP-MRI was more accurate than MP-MRI for identifying residual disease after NAC. A negative BP-MRI was associated with better outcomes, providing complementary information to pathological assessment of cystectomy specimens.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40644-023-00632-0","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:02:24Z","timestamp":1699956144000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-8369","authenticated-orcid":false,"given":"Sungmin","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeeban P.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soleen","family":"Ghafoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Benfante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Gangai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Yuen","family":"Teo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin C.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hebert A.","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"issue":"5","key":"632_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3322\/caac.21631","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced Bladder cancer in 2020. CA Cancer J Clin. 2020;70(5):404\u201323.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"632_CR2","first-page":"CD005246","volume":"2004","author":"Advanced Bladder Cancer Overview Collaboration","year":"2005","unstructured":"Advanced Bladder Cancer Overview Collaboration. Neoadjuvant chemotherapy for invasive Bladder cancer. Cochrane Database Syst Rev. 2005;2004(2):CD005246.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"632_CR3","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced Bladder cancer. N Engl J Med. 2003;349(9):859\u201366.","journal-title":"N Engl J Med"},{"issue":"16","key":"632_CR4","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","volume":"29","author":"Finnbladder","year":"2011","unstructured":"International Collaboration of Trialists, Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive Bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol off J Am Soc Clin Oncol. 2011;29(16):2171\u20137.","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"issue":"18","key":"632_CR5","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2013.52.4785","volume":"32","author":"TK Choueiri","year":"2014","unstructured":"Choueiri TK, Jacobus S, Bellmunt J, Qu A, Appleman LJ, Tretter C, et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol off J Am Soc Clin Oncol. 2014;32(18):1889\u201394.","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"issue":"2","key":"632_CR6","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.urology.2008.03.017","volume":"72","author":"F Koga","year":"2008","unstructured":"Koga F, Yoshida S, Kawakami S, Kageyama Y, Yokoyama M, Saito K, et al. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive Bladder cancer: an intent-to-treat survival analysis. Urology. 2008;72(2):384\u20138.","journal-title":"Urology"},{"issue":"2","key":"632_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","volume":"65","author":"F Petrelli","year":"2014","unstructured":"Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Vavassori I, Barni S. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in Bladder cancer treated with cystectomy: a meta-analysis. Eur Urol. 2014;65(2):350\u20137.","journal-title":"Eur Urol"},{"issue":"4","key":"632_CR8","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2214\/ajr.180.4.1801045","volume":"180","author":"V Kundra","year":"2003","unstructured":"Kundra V, Silverman PM. Imaging in oncology from the University of Texas M. D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am J Roentgenol. 2003;180(4):1045\u201354.","journal-title":"AJR Am J Roentgenol"},{"key":"632_CR9","doi-asserted-by":"publisher","first-page":"108902","DOI":"10.1016\/j.ejrad.2020.108902","volume":"126","author":"SJ Choi","year":"2020","unstructured":"Choi SJ, Park KJ, Lee G, Kim MH, Kim JK. Urothelial phase CT for assessment of pathologic complete response after neoadjuvant chemotherapy in muscle-invasive Bladder cancer. Eur J Radiol. 2020;126:108902.","journal-title":"Eur J Radiol"},{"issue":"3","key":"632_CR10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.euo.2020.02.007","volume":"3","author":"S Woo","year":"2020","unstructured":"Woo S, Panebianco V, Narumi Y, Del Giudice F, Muglia VF, Takeuchi M, et al. Diagnostic performance of Vesical Imaging Reporting and Data System for the prediction of muscle-invasive Bladder Cancer: a systematic review and Meta-analysis. Eur Urol Oncol. 2020;3(3):306\u201315.","journal-title":"Eur Urol Oncol"},{"issue":"7","key":"632_CR11","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00345-022-03969-6","volume":"40","author":"F Del Giudice","year":"2022","unstructured":"Del Giudice F, Flammia RS, Pecoraro M, Moschini M, D\u2019Andrea D, Messina E, et al. The accuracy of Vesical Imaging-Reporting and Data System (VI-RADS): an updated comprehensive multi-institutional, multi-readers systematic review and meta-analysis from diagnostic evidence into future clinical recommendations. World J Urol. 2022;40(7):1617\u201328.","journal-title":"World J Urol"},{"issue":"5","key":"632_CR12","doi-asserted-by":"publisher","first-page":"W226","DOI":"10.2214\/AJR.18.19880","volume":"211","author":"S Woo","year":"2018","unstructured":"Woo S, Suh CH, Kim SY, Cho JY, Kim SH, Moon MH. Head-to-head comparison between Biparametric and multiparametric MRI for the diagnosis of Prostate Cancer: a systematic review and Meta-analysis. AJR Am J Roentgenol. 2018;211(5):W226\u201341.","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"632_CR13","first-page":"20","volume":"22","author":"TGM Bricio","year":"2022","unstructured":"Bricio TGM, Gouvea GL, Barros RV, Chahud F, Elias J, Reis RB, et al. What is the impact of dynamic contrast-enhancement sequence in the Vesical Imaging, Reporting and Data System (VI-RADS)? A subgroup analysis. Cancer Imaging off Publ Int Cancer Imaging Soc. 2022;22(1):20.","journal-title":"Cancer Imaging off Publ Int Cancer Imaging Soc"},{"issue":"11","key":"632_CR14","first-page":"6341","volume":"35","author":"L Manganaro","year":"2015","unstructured":"Manganaro L, Anastasi E, Porpora MG, Vinci V, Saldari M, Bernardo S, et al. Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to improve characterization of large ovarian masses. Anticancer Res. 2015;35(11):6341\u201351.","journal-title":"Anticancer Res"},{"issue":"3","key":"632_CR15","doi-asserted-by":"publisher","first-page":"108e1","DOI":"10.1016\/j.urolonc.2021.09.017","volume":"40","author":"S Woo","year":"2022","unstructured":"Woo S, Ghafoor S, Das JP, Gangai N, Goh AC, Vargas HA. Plasmacytoid urothelial carcinoma of the bladder: MRI features and their association with survival. Urol Oncol. 2022;40(3):108e1\u201310.","journal-title":"Urol Oncol"},{"issue":"7","key":"632_CR16","first-page":"345e9","volume":"40","author":"JP Das","year":"2022","unstructured":"Das JP, Woo S, Ghafoor S, Andrieu PIC, Ulaner GA, Donahue TF, et al. Value of MRI in evaluating urachal carcinoma: a single center retrospective study. Urol Oncol Semin Orig Investig. 2022;40(7):345e9\u201317.","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"5","key":"632_CR17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.eururo.2019.12.016","volume":"77","author":"A Necchi","year":"2020","unstructured":"Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Far\u00e8 E, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in muscle-invasive Bladder Cancer: preliminary findings from the PURE-01 study. Eur Urol. 2020;77(5):636\u201343.","journal-title":"Eur Urol"},{"issue":"1","key":"632_CR18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00261-013-0038-0","volume":"39","author":"Hjun Wang","year":"2014","unstructured":"Wang Hjun, Pui MH, Guo Y, Yang D, Pan B, tao. Zhou X Hui. Diffusion-weighted MRI in bladder carcinoma: the differentiation between Tumor recurrence and benign changes after resection. Abdom Imaging. 2014;39(1):135\u201341.","journal-title":"Abdom Imaging"},{"issue":"2","key":"632_CR19","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.urology.2009.06.111","volume":"75","author":"S Yoshida","year":"2010","unstructured":"Yoshida S, Koga F, Kawakami S, Ishii C, Tanaka H, Numao N, et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive Bladder cancer. Urology. 2010;75(2):387\u201391.","journal-title":"Urology"},{"issue":"12","key":"632_CR20","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.ejrad.2013.08.008","volume":"82","author":"SB Donaldson","year":"2013","unstructured":"Donaldson SB, Bonington SC, Kershaw LE, Cowan R, Lyons J, Elliott T, et al. Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol. 2013;82(12):2161\u20138.","journal-title":"Eur J Radiol"},{"issue":"3","key":"632_CR21","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1148\/radiol.210875","volume":"302","author":"AG Wibmer","year":"2022","unstructured":"Wibmer AG, Nikolovski I, Chaim J, Lakhman Y, Lefkowitz RA, Sala E, et al. Local extent of Prostate Cancer at MRI versus Prostatectomy Histopathology: associations with Long-term oncologic outcomes. Radiology. 2022;302(3):595\u2013602.","journal-title":"Radiology"},{"issue":"19","key":"632_CR22","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1200\/JCO.2017.75.0158","volume":"36","author":"G Iyer","year":"2018","unstructured":"Iyer G, Balar AV, Milowsky MI, Bochner BH, Dalbagni G, Donat SM, et al. Multicenter prospective phase II trial of Neoadjuvant dose-dense Gemcitabine Plus Cisplatin in patients with muscle-invasive Bladder Cancer. J Clin Oncol off J Am Soc Clin Oncol. 2018;36(19):1949\u201356.","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"issue":"1","key":"632_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.2214\/AJR.15.15894","volume":"207","author":"S Woo","year":"2016","unstructured":"Woo S, Kim SY, Cho JY, Kim SH. Preoperative evaluation of Prostate Cancer aggressiveness: using ADC and ADC ratio in determining Gleason Score. AJR Am J Roentgenol. 2016;207(1):114\u201320.","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"632_CR24","doi-asserted-by":"publisher","first-page":"W374","DOI":"10.2214\/AJR.17.18283","volume":"209","author":"S Woo","year":"2017","unstructured":"Woo S, Suh CH, Kim SY, Cho JY, Kim SH. Diagnostic performance of DWI for differentiating high- from low-Grade Clear Cell Renal Cell Carcinoma: a systematic review and Meta-analysis. AJR Am J Roentgenol. 2017;209(6):W374\u201381.","journal-title":"AJR Am J Roentgenol"},{"issue":"6","key":"632_CR25","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1007\/s00261-021-02963-7","volume":"46","author":"SA Ahmed","year":"2021","unstructured":"Ahmed SA, Taher MGA, Ali WA, Ebrahem MAES. Diagnostic performance of contrast-enhanced dynamic and diffusion-weighted MR imaging in the assessment of Tumor response to neoadjuvant therapy in muscle-invasive Bladder cancer. Abdom Radiol N Y. 2021;46(6):2712\u201321.","journal-title":"Abdom Radiol N Y"},{"issue":"5","key":"632_CR26","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.euo.2020.06.004","volume":"4","author":"M Bandini","year":"2021","unstructured":"Bandini M, Calareso G, Raggi D, Marandino L, Colecchia M, Gallina A, et al. The Value of Multiparametric Magnetic Resonance Imaging Sequences to assist in the decision making of muscle-invasive Bladder Cancer. Eur Urol Oncol. 2021;4(5):829\u201333.","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"632_CR27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00261-021-03383-3","volume":"47","author":"S Aslan","year":"2022","unstructured":"Aslan S, Cakir IM, Oguz U, Bekci T, Demirelli E. Comparison of the diagnostic accuracy and validity of biparametric MRI and multiparametric MRI-based VI-RADS scoring in Bladder cancer; is contrast material really necessary in detecting muscle invasion? Abdom Radiol N Y. 2022;47(2):771\u201380.","journal-title":"Abdom Radiol N Y"},{"key":"632_CR28","doi-asserted-by":"crossref","unstructured":"Thompson HM, Bates DDB, Pernicka JG, Park SJ, Nourbakhsh M, Fuqua JL et al. MRI Assessment of Extramural Venous Invasion before and after total neoadjuvant therapy for locally advanced rectal Cancer and its Association with Disease-Free and overall survival. Ann Surg Oncol. 2023.","DOI":"10.1245\/s10434-023-13290-0"},{"issue":"2","key":"632_CR29","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00261-021-03365-5","volume":"47","author":"M Pecoraro","year":"2022","unstructured":"Pecoraro M, Del Giudice F, Magliocca F, Simone G, Flammia S, Leonardo C, et al. Vesical Imaging-Reporting and Data System (VI-RADS) for assessment of response to systemic therapy for Bladder cancer: preliminary report. Abdom Radiol N Y. 2022;47(2):763\u201370.","journal-title":"Abdom Radiol N Y"},{"key":"632_CR30","doi-asserted-by":"crossref","unstructured":"Wu J, Xie RY, Cao CZ, Shang BQ, Shi HZ, Shou JZ. Disease Management of Clinical Complete Responders to Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer: A Review of Literature. Front Oncol [Internet]. 2022 [cited 2023 May 4];12. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9043546\/.","DOI":"10.3389\/fonc.2022.816444"},{"issue":"16suppl","key":"632_CR31","doi-asserted-by":"publisher","first-page":"TPS4615","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4615","volume":"40","author":"G Iyer","year":"2022","unstructured":"Iyer G, Ballman KV, Atherton PJ, Murray K, Kwok Y, Steen PD, et al. A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive Bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701). J Clin Oncol. 2022;40(16suppl):TPS4615\u20135.","journal-title":"J Clin Oncol"},{"key":"632_CR32","doi-asserted-by":"publisher","first-page":"961393","DOI":"10.3389\/fonc.2022.961393","volume":"12","author":"S Hafeez","year":"2022","unstructured":"Hafeez S, Koh M, Jones K, Ghzal AE, D\u2019Arcy J, Kumar P, et al. Diffusion-weighted MRI to determine response and long-term clinical outcomes in muscle-invasive Bladder cancer following neoadjuvant chemotherapy. Front Oncol. 2022;12:961393.","journal-title":"Front Oncol"},{"issue":"6","key":"632_CR33","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.ejrad.2015.02.026","volume":"84","author":"C Chakiba","year":"2015","unstructured":"Chakiba C, Cornelis F, Descat E, Gross-Goupil M, Sargos P, Roubaud G, et al. Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma. Eur J Radiol. 2015;84(6):1023\u20138.","journal-title":"Eur J Radiol"},{"issue":"10","key":"632_CR34","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.3390\/cancers12102994","volume":"12","author":"F Del Giudice","year":"2020","unstructured":"Del Giudice F, Pecoraro M, Vargas HA, Cipollari S, De Berardinis E, Bicchetti M, et al. Systematic review and Meta-analysis of Vesical Imaging-Reporting and Data System (VI-RADS) Inter-observer Reliability: an added value for muscle invasive Bladder Cancer detection. Cancers. 2020;12(10):2994.","journal-title":"Cancers"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-023-00632-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-023-00632-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-023-00632-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:02:45Z","timestamp":1699956165000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerimagingjournal.biomedcentral.com\/articles\/10.1186\/s40644-023-00632-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["632"],"URL":"https:\/\/doi.org\/10.1186\/s40644-023-00632-0","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the institutional review board of Memorial Sloan Kettering Cancer Center, and the requirement for signed informed consent was waived due to the retrospective study design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MYT has equity interests at Clovis Oncology and provides services to Janssen Global Services, LLC. ACG is a consultant to Medtronics for provision of Services for which he does not receive compensation. The other authors do not have anything to disclose. Aforementioned entities were not involved in the design, conduct, or manuscript writing of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}